BioSeek | GenomeWeb

BioSeek

NEW YORK (GenomeWeb News) – DiscoveRx today said that it has acquired BioSeek, maker of the BioMAP platform of cell-based disease models for drug screening.
Financial terms of the deal were not disclosed.

NEW YORK (GenomeWeb News) – BioSeek today said that the US Environmental Protection Agency has extended the firm's contract to participate in the ToxCast screening program.

A research team led by scientists at proteomics firm Cellzome has developed a selective inhibitor to the PI3 kinase isoform PI3Kγ.

Cellzome will use the BioMap platform in its inflammatory disease drug discovery projects.

BioSeek will apply its BioMap predictive human disease models to screen Amylin's library.

The Japanese pharmaceutical developer has licensed the BioMap platform for drug toxicology research projects.

BioSeek will use its BioMap system to conduct screening for Ono Pharmaceuticals in its compound studies.

The acquisition will combine Asterand's tissue-based services for drug discovery with BioSeek's BioMap platform and human cell-based assays.

The firm will profile compounds for the second phase of the EPA initiative.

Pages

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.